Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433203 | 0.84 | GAA (0.42) | RAB9AKDM4EMAPTSMN1; SMN2GAA | |
| SCHEMBL2428682 | 0.80 | GAA (0.58) | RAB9AKDM4ESMN1; SMN2GAAALDH1A1 | |
| SCHEMBL2538990 | 0.77 | RAB9A (0.72) | RAB9AKDM4EMAPTSMN1; SMN2GAA | |
| SCHEMBL2258303 | 0.77 | RAB9A (0.68) | RAB9AKDM4EMAPTSMN1; SMN2GAA | |
| SCHEMBL2538655 | 0.77 | RAB9A (0.68) | RAB9AKDM4EMAPTSMN1; SMN2GAA | |
| SCHEMBL2539673 | 0.71 | RAB9A (0.62) | RAB9AKDM4EMAPTSMN1; SMN2GAA | |
| SCHEMBL102644 | 0.71 | GAA (1.00) | RAB9AKDM4EGAAALDH1A1NPC1 | |
| SCHEMBL2428137 | 0.70 | NPC1 (0.65) | RAB9AKDM4EMAPTSMN1; SMN2GAA | |
| SCHEMBL12291859 | 0.70 | NPC1 (0.65) | RAB9AKDM4EMAPTSMN1; SMN2GAA | |
| SCHEMBL6608660 | 0.69 | GAA (0.96) | RAB9AKDM4EGAAALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1956013-B1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | FUJIFILM RI PHARMA CO LTD (JP) | 2016-04-13 | — | — | EP | claimed |
| EP-1956013-B1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | FUJIFILM RI PHARMA CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8022075-B2 | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition | FUJIFILM RI PHARMA CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20090162283-A1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | FUJIFILM RI PHARMA CO., LTD. (JP) | 2009-06-25 | — | — | US | disclosed |
| EP-1956013-A1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | Fujifilm RI Pharma Co., Ltd. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162283-A1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | APP, TTR, BACE1 | RAB9A 3111/4885KDM4E 3451/4885MAPT 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.